BUZZ-Raymond James resumes coverage on BridgeBio with 'outperform' on heart drug optimism

Brokerage Raymond James resumes coverage on drugmaker BridgeBio Pharma BBIO.O with "outperform" rating; sets PT at $57, a 66.4% upside to the stock's last close

Brokerage anticipates BBIO's launch of heart disease drug Attruby to be faster than expected, even with a significant discount on revenues after 2028 due to potential pricing pressure from the loss of exclusivity for Pfizer's PFE.N tafamidis

"We expect it to gain meaningful market share in the newly diagnosed population," brokerage adds

BBIO can leverage its drugs Encaleret and BBP-418 to form partnerships and improve finances — brokerage

14 out of 16 brokerages rate the stock "buy" or higher, 2 rate it "hold", per data compiled by LSEG

Stock has fallen 4.1% in the past 12 months